SCHEMBL2632910

SCHEMBL2632910

CCn1c(=O)c(-c2ccc(F)cc2F)cc2c(C)nc(NC)nc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 15/20 0.50
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
HSD17B10 Q99714 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
GAK O14976 1/20 0.43
ABL1 P00519 1/20 0.43
EPHA1 P21709 1/20 0.43
EPHA2 P29317 1/20 0.43
EPHA3 P29320 1/20 0.43
EPHB2 P29323 1/20 0.43
MAPK8 P45983 1/20 0.43
EPHB3 P54753 1/20 0.43
EPHB4 P54760 1/20 0.43
EPHB1 P54762 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188692 0.90 ALDH1A1 (0.60) PIK3CAKDM4EALDH1A1GLAGAA
SCHEMBL6128333 0.84 PIK3CA (0.60) PIK3CAMTORPIK3CDPIK3CBPIK3CG
SCHEMBL15580678 0.79 ALDH1A1 (0.48) PIK3CAKDM4EALDH1A1GLAGAA
SCHEMBL188697 0.78 ALDH1A1 (0.61) PIK3CAKDM4EALDH1A1GLAGAA
SCHEMBL15146960 0.78 PIK3CA (0.54) PIK3CAKDM4EALDH1A1GLAGAA
SCHEMBL189369 0.77 ALDH1A1 (0.63) PIK3CAKDM4EALDH1A1GLAGAA
SCHEMBL15109485 0.77 PIK3CA (0.51) PIK3CAKDM4EALDH1A1GLAGAA
SCHEMBL189553 0.76 PIK3CA (0.73) PIK3CAKDM4EALDH1A1GLAGAA
SCHEMBL188829 0.76 ALDH1A1 (0.58) PIK3CAKDM4EALDH1A1GLAGAA
SCHEMBL189179 0.75 KDM4E (0.79) PIK3CAKDM4EALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056829-B9 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS INC (US) 2012-09-26 EP disclosed
EP-2056829-B1 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS INC (US) 2012-01-04 EP disclosed